Core Viewpoint - The article highlights significant movements in the stock market, particularly focusing on the performance of various companies and sectors, driven by recent news and market conditions. Group 1: Mobile Industry - The mobile supply chain continues to decline, with companies like Hon Teng Precision (06088) down 6.93%, Lens Technology (06613) down 6.5%, and others facing similar drops due to a shortage of memory chips and rising prices affecting shipment plans for 2026, leading to a projected 7.3% decrease in global mobile panel shipments from 2025 to 2026 [1] Group 2: Shipping and Energy - China COSCO Shipping Energy Transportation (01138) fell over 8.1% amid escalating US-Iran conflicts affecting shipping in the Strait of Hormuz, with reports indicating a significant reduction in vessel traffic [1] Group 3: AI and Technology - MiniMax (00100) saw a rise of over 5% due to its association with the OpenClaw AI ecosystem, transitioning from a technology validation phase to a monetization phase [2] - InSilico Medicine (03696) increased by over 7% following a strategic partnership with Liquid AI to develop a lightweight scientific model for pharmaceutical research, achieving industry-leading performance in drug discovery benchmarks [2] Group 4: Agriculture and Livestock - Original Ecology Livestock (01431) surged over 18.3% after announcing expected net profits between RMB 5.2 billion and RMB 5.7 billion for the fiscal year ending December 31, 2025, compared to RMB 2.97 billion for the fiscal year ending December 31, 2024 [2] Group 5: Restaurant Sector - Xia Bo Xia Bo (00520) dropped nearly 17%, reaching a new low of HKD 0.59, with projected revenues of approximately RMB 3.8 billion for 2025 and a net loss of RMB 290 million to RMB 310 million, although this represents a reduction of 22.2% to 27.2% compared to 2024 [3][4] Group 6: Banking Sector - Hong Kong bank stocks continued to decline, with Standard Chartered (02888) down 4.88% and Bank of China Hong Kong (02388) down 4.12%, amid uncertainties in the Gulf region affecting Asian banks' loan exposure [3] Group 7: Stock Market Movements - Mini Med Group (MMED.US) debuted on the US stock market with a 7.55% drop from its IPO price of $20, while Marvell Technology (MRVL.US) rose 18.35% due to strong earnings and revenue outlook [6] - Blue Owl Capital (OWL.US) fell 5.09% amid concerns over exposure to a bankrupt UK real estate loan company [8] - Major tech stocks like Meta (META.US) and Tesla (TSLA.US) experienced declines, contributing to a broader market downturn with the Nasdaq down 1.49% [8]

Core Viewpoint - Medtronic is strategically appointing Chad Spooner as CFO of its diabetes division MiniMed to support the upcoming spin-off into an independent publicly traded company, aiming to establish a solid financial and strategic foundation for future growth [1][8]. Group 1: Appointment of Chad Spooner - Chad Spooner will officially take on the role of CFO for MiniMed starting July 14, 2025, coinciding with Medtronic's plans to spin off its diabetes business [1]. - Spooner brings over 25 years of financial leadership experience across various sectors, including healthcare and consumer goods, which will be crucial for MiniMed's transition to independence [6][9]. - His previous roles include CFO at BIC Group and co-founder of Tenex Capital Management, providing him with extensive experience in financial strategy and capital market operations [6][9]. Group 2: MiniMed's Spin-off Strategy - Medtronic announced plans to separate its diabetes business into an independent publicly traded company, expected to be completed within 18 months [3]. - MiniMed will focus on comprehensive insulin management systems, including automated insulin pumps and continuous glucose monitoring devices [3]. - The business model is shifting from traditional B2B to a direct-to-consumer (B2C) approach, emphasizing consumer experience and market responsiveness [9]. Group 3: Financial Implications and Market Response - Spooner's appointment is seen as a move to enhance investor confidence and improve market expectations regarding MiniMed's operational capabilities post-spin-off [10]. - Medtronic's fiscal year 2025 report indicated strong financial performance with total revenue of $33.537 billion and net income of $4.662 billion, which supports the rationale behind the spin-off [10]. - The stock price of Medtronic rose nearly 10% following the announcement of the spin-off, indicating positive market sentiment [10]. Group 4: Future Prospects and Innovations - MiniMed is at a critical stage of technological innovation, including collaborations on new continuous glucose monitoring systems and automated insulin delivery systems [9]. - Spooner's financial leadership is expected to provide necessary funding and resource allocation for high-potential projects, facilitating their transition from research and development to market [9]. - The strategic appointment of Spooner is anticipated to strengthen MiniMed's financial execution and market adaptability during this transformative phase [11].